Scholar Rock has two Miami investor talks scheduled on consecutive days.
Scholar Rock (NASDAQ: SRRK) announced that its management will participate in two upcoming investor conferences in Miami: the 9th Annual Evercore Healthcare Conference on December 1, 2026, and the Citi 2026 Global Healthcare Conference on December 2, 2026. The company, focused on neuromuscular diseases, will host fireside chats at both events, with webcasts available on its investor relations website.
Four Wellington entities report identical share counts but differing stakes in Scholar Rock (SRRK).
Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP have filed an amended beneficial ownership report for Scholar Rock Holding Corp. (SRRK) as of September 30, 2026. Each entity reported beneficially owning 8,708,303 shares. However, their reported ownership percentages vary, with three entities stating 7.2% and Wellington Management Company LLP stating 6.8%.
Six new hires get Scholar Rock stock awards with four-year vesting schedules
Scholar Rock (NASDAQ: SRRK) announced inducement equity awards for six new employees, totaling 39,587 shares of common stock. These awards, consisting of stock options and restricted stock units, are granted under the company's 2022 Inducement Equity Plan and are subject to four-year vesting schedules. The inducement is part of the company's strategy to attract new talent as permitted by Nasdaq Listing Rule 5635(c)(4).
Scholar Rock Holding Q3 2026 Earnings Call Transcript
Scholar Rock Holding (NASDAQ: SRRK) reported its Q3 2026 financial results, including $0.6 million in Isemble revenue and $413.6 million in cash. The company is actively launching Isemble in the US, with strong initial patient demand despite expected reimbursement and access delays, and is preparing for launches in Europe and Japan by late 2027. Scholar Rock also monetized a priority review voucher for $205 million, bolstering its financial position to fund global commercial and R&D initiatives.
Scholar Rock Holding Corp. (SRRK) Tops Q3 EPS by 3c
Scholar Rock Holding Corp. (SRRK) reported its Q3 earnings, surpassing analyst EPS estimates by $0.03 with a reported ($0.81) per share. However, the company's revenue of $570 thousand fell short of the consensus estimate of $1.43 million. The stock experienced a decline of 6.89% on the day.
Scholar Rock to Sell FDA Priority Review Voucher to BioNTech for $205 Million
Scholar Rock has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher to BioNTech for $205 million in cash. The payment is due at closing, subject to customary conditions including the Hart-Scott-Rodino waiting period. This transaction allows Scholar Rock to monetize a voucher it received after the FDA approval of ISEMBYLD.
Scholar Rock Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Scholar Rock announced its Q3 2026 financial results, reporting a net loss of $107.2 million and net product revenue of $0.6 million from its newly approved SMA drug, ISEMBYLD. The company is progressing with the U.S. launch of ISEMBYLD, with strong early demand, and advancing regulatory applications in Europe and Japan. Scholar Rock also entered a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for $205 million, strengthening its financial position.
SRRK: Scholar Rock Holding Corporation filed SEC Form 8-K: Entry...
Scholar Rock Holding Corporation announced the sale of its Rare Pediatric Disease Priority Review Voucher to BioNTech US for $205 million in cash, which will provide non-dilutive capital. This comes after the Q3 2026 report showing ISEMBYLD revenue of $0.6 million and a net loss of $107.2 million, or $0.81 per share, with $413.6 million in cash and marketable securities. The closing of the PRV sale is subject to regulatory conditions.
Form 8K Scholar Rock Holding Corp For: 10 November By Investing.com
This article reports on Scholar Rock Holding Corp's (SRRK) Form 8K filing for November 10. The filing is a standard disclosure for public companies, indicating significant events or information for investors. The article reiterates the filing multiple times and notes the stock's minor price change.
Scholar Rock earnings loom as first Isembyld sales take focus
Scholar Rock Holding Corp. is preparing to report its third-quarter results, with investor focus primarily on the initial commercial sales of its new muscle-targeted treatment, Isembyld, following its FDA approval in September. Analysts anticipate a loss of $0.84 per share and revenue of $1.43 million, marking the company's first sales. Despite a recent stock slide, Wall Street maintains a bullish outlook, with a consensus price target suggesting significant upside.
Will ISEMBLYD Launch Change Scholar Rock Stock Narrative
Scholar Rock Holding is advancing the commercialization of ISEMBLYD for spinal muscular atrophy, with plans for a 50-country rollout, despite reporting no current profits and a sharp year-on-year revenue drop. The company's investment narrative hinges on ISEMBLYD's success transitioning it to a commercial rare disease platform and achieving significant revenue and earnings growth by 2029. However, this strategy faces risks related to uptake, reimbursement, and real-world outcomes, which must keep pace with the substantial costs and debt incurred.
UBS and Jefferies conferences are set to feature Scholar Rock in London Nov. 16 and 17
Scholar Rock (NASDAQ: SRRK) announced that its management will participate in investor conference fireside chats in London on November 16 and 17, 2026. The company is scheduled to speak at the UBS Global Biopharma Conference and the Jefferies Global Healthcare Conference. These presentations will be available via live webcast and replay on the company's investor relations website.
Scholar Rock Holding (SRRK) Stock Price, Chart & Analysis
This article provides an analysis of Scholar Rock Holding (SRRK) stock, including its latest price of $43.98 as of November 3, 2026, and a market cap of $5.23 billion. It details key financial figures such as revenue growth, net margin, and debt status, noting that the company pays no dividend and has more cash than debt. The analysis also covers analyst expectations for revenue and earnings growth, along with a price target.
Srinivas Akkaraju Acquires 289,470 Shares of Scholar Rock (SRRK) Between October 23-26, 2026
Director Srinivas Akkaraju, through affiliated investment funds, purchased 289,470 shares of Scholar Rock Holding Corp (SRRK) common stock between October 23 and October 26, 2026. The open-market transactions were executed at weighted average prices ranging from $41.31 to $41.82 per share. Following these purchases, the affiliated funds, Samsara BioCapital, L.P. and Samsara Opportunity Fund, L.P., held over 7 million shares combined, though Akkaraju disclaims beneficial ownership beyond his pecuniary interest.
Form 4 Scholar Rock Holding Corp: Srinivas Akkaraju (Director) For: 23 October
This article reports on a Form 4 filing for Scholar Rock Holding Corp, specifically detailing a transaction by Director Srinivas Akkaraju on October 23rd. The filing indicates insider trading activity, which is typically of interest to investors tracking company-specific developments. The article provides minimal details beyond the core announcement, as is common for automated Form 4 reporting.
Scholar Rock director Akkaraju buys $12 million in shares By Investing.com
Srinivas Akkaraju, a director at Scholar Rock Holding Corp, acquired approximately $12 million worth of common stock between October 23 and October 26, 2026, through investment entities. Despite the company being unprofitable with a -$3.36 EPS, the stock has seen a 42% return over the past year. Analyst firms Truist Securities, Raymond James, and Piper Sandler have reiterated "Buy" or "Overweight" ratings, setting price targets between $72.00 and $77.00, based on Isembyld treatment potential and regulatory advancements.
Two funds buy Scholar Rock (SRRK) shares as director Akkaraju reports six purchases.
Scholar Rock Holding Corp (SRRK) director Srinivas Akkaraju reported that two funds, Samsara BioCapital, L.P. and Samsara Opportunity Fund, L.P., purchased a total of 289,470 common shares. These six transactions occurred on October 23 and October 26, 2026, at weighted-average prices between $41.31 and $41.82 per share. Additionally, Akkaraju directly holds 27,971 common shares as of October 23, 2026.
Scholar Rock (SRRK) Stock Looks Overvalued Against Its Book Value
Scholar Rock Holding (SRRK) is deemed overvalued based on its book value, trading at a P/B of 19.9x compared to an industry average of 1.8x. This premium suggests the market is placing significant value on the company's research pipeline and balance sheet strength relative to its current equity base. The article questions whether Scholar Rock's assets and progress justify paying nearly 20 times its book value.
Weekly Recap: ISEMBYLD to up to 50 countries and Q3'26 results Nov.10
Scholar Rock Holding Corp. (NASDAQ:SRRK) announced plans to expand the availability of its drug ISEMBYLD to as many as 50 countries following U.S. approval. The company is also scheduled to report its Q3 2026 results on November 10, before the market opens, and will host a preregistered conference call for investors.
Is Scholar Rock Holding (SRRK) Undervalued As Its Commercial Buildout Faces A Valuation Test?
Scholar Rock Holding (SRRK) has experienced mixed share price returns recently, with a monthly decline but strong multi-year gains. Despite a current trading price of $41.49, analysts estimate its fair value at $70.44, suggesting it is 41% undervalued. This valuation hinges on successful FDA reinspections and the real-world efficacy of apitegromab, while the company strengthens its commercial infrastructure to support broad access.
Scholar Rock Holding Corp. Estimates – LSX:A2JMQW
This page on TradingView provides financial estimates and data for Scholar Rock Holding Corp. (LSX:A2JMQW). Users can explore reported financial data and analyst estimates across various financial statements and visualize trends over time. The platform also includes a disclaimer emphasizing that the information is not investment advice.
Cost of goods sold of Scholar Rock Holding Corp. – HAN:2QK
This article displays the cost of goods sold for Scholar Rock Holding Corp. (HAN:2QK) on the Hannover Stock Exchange. It indicates that the market is currently closed with no trades. The article is part of a financial data overview for the company.
Scholar Rock Holding Corporation (SRRK) stock price, news, quote and history
This Yahoo Finance page provides comprehensive financial data for Scholar Rock Holding Corporation (SRRK), including its current stock price, recent news, historical data, and analyst insights. The company is a biopharmaceutical firm focused on treatments for SMA and other neuromuscular diseases, with recent FDA approvals and fast-track designations for its key drug candidates. The stock's performance, earnings trends, and valuation measures are also detailed.
Scholar Rock resubmits EU application for SMA treatment By Investing.com
Scholar Rock has resubmitted its Marketing Authorisation Application for apitegromab, an SMA treatment, to the European Medicines Agency. The resubmission follows the withdrawal of an earlier application due to GMP compliance issues at a previous fill-finish facility, now replaced by the same facility that supported U.S. FDA approval. The company anticipates an opinion from the Committee for Medicinal Products for Human Use in the first half of 2027.
Scholar Rock Holding Reports Q2 2026 Results: Full Earnings Call Transcript
Scholar Rock Holding reported its Q2 2026 financial results, highlighting preparations for the U.S. launch of apitegromab by September 30th, with two fill-finish facilities secured for approval. The company ended the quarter with $492 million in cash and is advancing its anti-myostatin pipeline, including the Phase 2 OPAL trial for SMA and the FORGE study for FSHD. Scholar Rock is also preparing for the European market, starting with Germany, and maintaining strong engagement with both FDA and EMA for regulatory approvals.
Director Katie Peng proposes selling 1,006 shares of Scholar Rock (SRRK).
Scholar Rock Holding Corp. director Katie Peng has filed a notice to sell 1,006 common shares of SRRK, valued at approximately $48,610, with an anticipated sale date of October 1, 2026. The proposed sale includes shares from RSU transactions on August 15 and September 15, 2026. J.P. Morgan Securities LLC is listed as the broker for this transaction.
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm
Kuehn Law is encouraging investors of Scholar Rock Holding Corp (SRRK) to contact their law firm. The article is a headline-only news item from PR Newswire, indicating potential legal action or investigation related to the company.
Investigation launched into Scholar Rock's officers for possible self-dealing harming shareholders
Kuehn Law, PLLC has initiated an investigation into Scholar Rock Holding Corp's officers and directors regarding potential breaches of fiduciary duties and self-dealing that may harm shareholders. This probe could lead to shareholder damages and corporate governance reforms, prompting long-term shareholders to seek legal consultation. The case underscores broader concerns about management integrity and the protection of shareholder interests at the company.
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm
Kue
Net income of Scholar Rock Holding Corp. – HAN:2QK
The article focuses on the net income of Scholar Rock Holding Corp. (HAN:2QK) as listed on the Hannover Stock Exchange. It indicates that the market is currently closed with no trades recorded. The content is primarily a data placeholder within a financial platform, showing basic financial information for the company.
Form 4 Scholar Rock Holding Corp For: 26 September By Investing.com
This Investing.com article announces the filing of a Form 4 for Scholar Rock Holding Corp on September 26, 2026. The content is very brief and primarily serves as a placeholder or notification of the regulatory filing, without providing details about the filing itself. The majority of the page is filled with navigation links, market data, and unrelated news summaries.
No common shares appear in Scholar Rock (SRRK) COO Keith Woods’s reported position after a gift to a trust.
Scholar Rock Holding Corp (SRRK) COO Keith Woods gifted 48,034 common shares to the RKW Irrevocable Trust on September 24, 2026. Following this transaction, Woods's reported position lists 0 common shares, but includes 122,021 time-based RSUs and 450,000 performance- and time-based RSUs. He disclaimed beneficial ownership of the trust shares except for his pecuniary interest.
Scholar Rock added to Wedbush's Best Ideas List
Wedbush has added Scholar Rock Holding Corp. (SRRK) to its Best Ideas List, citing the company's strong position for commercial growth in the neuromuscular sector. The firm projects a $70 price target for SRRK, indicating a potential 44% upside from its previous closing price. This positive outlook suggests confidence in Scholar Rock's future performance.
Wedbush Rates Scholar Rock (SRRK) Outperform Amid Attractive Price-to-Sales Opportunity
Wedbush has assigned an "Outperform" rating to Scholar Rock (SRRK), citing its promising neuromuscular pipeline and recent product launch, ISEMBYLD, as key growth drivers. Despite the company's current unprofitability and high Price-to-Sales ratio of 30.4x, Wedbush believes recent stock weakness presents an entry point for investors. The article highlights SRRK's moderate financial strength but notes a low GF Score of 29/100 due to profitability and momentum challenges, alongside mixed insider sentiment.
No payment changed hands when Scholar Rock (SRRK) CEO David Hallal transferred 36,652 shares to a family trust.
Scholar Rock Holding Corp (SRRK) CEO David Hallal transferred 36,652 common shares to The Hallal Family Irrevocable Trust-2021 on September 21, 2026, without any monetary exchange. After this transaction, Hallal's reported direct and indirect holdings totaled 1,602,382 shares, including common stock and various RSUs, with the trust directly holding the gifted shares. The Form 4 filing specifies that the CEO disclaims beneficial ownership of the securities held by the trusts beyond his pecuniary interest.
SRRK Maintains Overweight Rating by JP Morgan -- Price Target Ra
JP Morgan has reiterated an "Overweight" rating for Scholar Rock Holding Corp (SRRK), increasing its price target from $63.00 to $70.00. Despite this positive analyst outlook driven by its innovative pipeline in neuromuscular diseases, the company's GF Score™ is low at 29/100, indicating below-average performance in profitability and growth. Investors are cautioned due to the high price-to-sales ratio and mixed sentiment from institutional investors and insider selling activity.
Bank of America Corp DE Takes $53.47 Million Position in Scholar Rock Holding Corporation $SRRK
Bank of America Corp DE has acquired a new stake of 972,257 shares in Scholar Rock Holding Corporation (NASDAQ:SRRK), valued at approximately $53.47 million, representing about 0.8% of the company. Institutional investors now collectively own 91.08% of SRRK. Analyst sentiment remains positive, with a consensus "Buy" rating and an average price target of $66.00, while the company reported a quarterly EPS of -$0.84, meeting analyst expectations.
Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale?
Scholar Rock Holding Corporation (SRRK) received FDA approval for ISEMBYLD to treat spinal muscular atrophy (SMA) as an add-on to existing therapies. The drug demonstrated motor benefits in clinical trials, suggesting a complementary role to current treatments. However, its commercial success hinges on patient access, payer coverage, and managing the risk of fractures as a side effect.
Scholar Rock (NASDAQ: SRRK) Updates FDA Safety Requirements for ISEMBYLD Post-Approval
Scholar Rock (NASDAQ: SRRK) announced updates to the FDA's post-approval safety requirements for its drug ISEMBYLD, which is approved for spinal muscular atrophy. The company clarified that it is mandated to conduct a pregnancy safety study and report all serious and non-serious fracture cases globally as alert reports, correcting previous statements made during an investor call. Scholar Rock has committed to complying with these FDA requirements.
Form 8K Scholar Rock Holding Corp For: 15 September By Investing.com
This article reports on the filing of a Form 8K by Scholar Rock Holding Corp on September 15. The brief announcement provides no further details about the content of the filing. It includes the stock symbol SRRK and notes a slight decrease in its value.
SRRK Stock News Today | Earnings, Events & Price Alerts
This article provides recent news and events related to SRRK stock (Scholar Rock). Key updates include the FDA approval of Isembyld for SMA treatment, its fast-track and orphan drug designations, and a required post-marketing pregnancy safety study. The stock saw a 4% decline to $49.97 following the event details.
Barclays downgrades Scholar Rock stock rating on valuation
Barclays downgraded Scholar Rock (NASDAQ:SRRK) to Equalweight from Overweight and raised its price target to $58 from $55 following the FDA approval of apitegromab (Isembyld). The firm noted that the risk-reward profile is now more balanced, with future upside dependent on strong commercial execution and pipeline expansion beyond spinal muscular atrophy. Despite the approval, the company remains unprofitable, underscoring the importance of successful commercialization.
Timothy Springer-backed biotech hits milestone: FDA approves first-of-its-kind SMA therapy
Scholar Rock, a Cambridge-based biotech company backed by Harvard immunologist Timothy Springer, has received FDA approval for its first drug. This therapy is a first-of-its-kind treatment for muscle loss associated with spinal muscular atrophy (SMA). The approval marks a significant milestone for the company and its investors.
Form 8K Scholar Rock Holding Corp For: 14 September By Investing.com
This article reports on the filing of a Form 8K by Scholar Rock Holding Corp on September 14, 2026. The brief entry provides the company name and filing date, without further details on the content of the Form 8K. The article is published by Investing.com, a financial markets news service.
Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy
The FDA has approved Scholar Rock's ISEMBYLD (apitegromab-mstn) for spinal muscular atrophy (SMA) in patients aged 2 and older, marking it as the first muscle-targeted therapy to improve motor function in individuals already on SMN2-targeted drugs. This approval, backed by positive Phase 3 SAPPHIRE study results, also earned Scholar Rock a Rare Pediatric Disease Priority Review Voucher. The company has begun the U.S. commercial launch of ISEMBYLD, which targets promyostatin and latent myostatin to inhibit myostatin activation.
Why is Scholar Rock stock surging 9% today?
Scholar Rock Holding Corp (SRRK) stock surged over 9% after the FDA approved ISEMBYLD for spinal muscular atrophy, making it the first muscle-targeted treatment for the condition. This approval, which came ahead of schedule and with a broad label, transformed Scholar Rock into a commercial biopharmaceutical company. Analysts responded by significantly raising price targets, further boosting investor confidence despite a broader market downturn.
BMO reiterates Scholar Rock stock Outperform on SMA drug uptake
BMO Capital has reiterated an Outperform rating and a $76.00 price target for Scholar Rock (NASDAQ: SRRK) due to the anticipated broad usage of its SMA drug, apitegromab. A physician survey indicated significant potential for the drug in combination with SMN-directed therapy, with most surveyed neurologists planning to prescribe it upon approval. Despite the stock's 75% surge over the past year, InvestingPro data suggests it may be overvalued compared to its Fair Value estimate.
Bank of New York Mellon Corp Acquires New Shares in Scholar Rock Holding Corporation $SRRK
Bank of New York Mellon Corp has acquired 365,218 shares of Scholar Rock Holding Corporation (NASDAQ:SRRK), valued at approximately $20.1 million, establishing a 0.30% stake in the company. Institutional investors now collectively own 91.08% of Scholar Rock, which has a consensus "Buy" rating and an average price target of $58.77 from Wall Street analysts. The clinical-stage biotech recently reported quarterly EPS of -$0.84, aligning with analyst expectations, and its stock opened near its 52-week high at $57.80.
Scholar Rock Holding Corp stock hits 52-week high at 58.52 USD
Scholar Rock Holding Corp (SRRK) stock recently reached a 52-week high of $58.52, reflecting a 59% total return over the past year and a 74.02% one-year change. Despite appearing overvalued, the company reported a narrower-than-expected Q2 loss and is on track for a U.S. regulatory decision for its lead drug, apitegromab, by September 30. Analyst firms BMO Capital and H.C. Wainwright have reiterated "Outperform" and "Buy" ratings respectively, with price targets of $76.00 and $65.00.
Scholar Rock to Present at Upcoming Investor Conferences
Scholar Rock, a biopharmaceutical company, announced its participation in two upcoming investor conferences: the Cantor 2026 Global Healthcare Conference and the Citi 2026 BioPharma Back to School Conference. Management will engage in fireside chats at both events in New York, NY, on September 9 and September 10, 2026, respectively. Webcasts of these presentations will be available on the company's investor relations website.